Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Merck
Dow
Medtronic
Johnson and Johnson

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

XULTOPHY 100 Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Xultophy 100, and when can generic versions of Xultophy 100 launch?

Xultophy 100 is a drug marketed by Novo and is included in one NDA. There are twenty-one patents protecting this drug.

The generic ingredient in XULTOPHY 100 is insulin degludec; liraglutide. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin degludec; liraglutide profile page.

Summary for XULTOPHY 100
US Patents:0
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:XULTOPHY 100 at DailyMed
Drug patent expirations by year for XULTOPHY 100

Notice: You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near ') ORDER BY p.submissiondate DESC' at line 2 in /home/thinkbio/public_html/drugpatentwatch/inc/modules/sm/summary_piv.php on line 32

Warning: mysqli_num_rows() expects parameter 1 to be mysqli_result, boolean given in /home/thinkbio/public_html/drugpatentwatch/inc/modules/sm/summary_piv.php on line 34

US Patents and Regulatory Information for XULTOPHY 100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
Harvard Business School
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.